Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations
Clinical trial NCT01470716 · UNKNOWN
Trial details
- NCT number
- NCT01470716
- Sponsor
- National Cancer Center, Korea
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-01-01
- Primary completion
- 2021-12-31
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.